Regulatory

Regulatory  ·  Weekly Digest - 20 September to 26 September 2025
Enhertu plus Pertuzumab granted priority review in the US as 1st-line treatment for patients with HER2-positive metastatic breast cancer

Weekly Digest – September 2025 Weekly Digest – September 2025 24 September 2025: Enhertu plus Pertuzumab granted priority review in the US as 1st-line treatment for patients with HER2-positive metastatic breast cancer The FDA has granted priority review to Enhertu […]

by Sandhya Ramalingam

Continue Reading
Regulatory  ·  Weekly Digest - 20 September to 26 September 2025
Huadong Medicine’s CDH17-targeted ADC HDM2017 IND application received FDA approval in the US

Weekly Digest – September 2025 Weekly Digest – September 2025 22 September 2025: Huadong Medicine’s CDH17-targeted ADC HDM2017 IND application received FDA approval in the US The U.S. FDA approved Huadong Medicine’s IND application for HDM2017, a CDH17-targeted ADC, allowing […]

by Sandhya Ramalingam

Continue Reading